Table I.
Association between clinical characteristics and PNI, ALI and AGR values in patients with advanced gastric cancer.
| PNI | ALI | AGR | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical characteristic |
|
|
|
||||||||||
| n | <45.5 | ≥45.5 | χ2 | P-value | <272.57 | ≥272.57 | χ2 | P-value | <1.40 | ≥1.40 | χ2 | P-value | |
| Total | 195 | 96 | 99 | 98 | 97 | 100 | 95 | ||||||
| Sex | |||||||||||||
| Female | 60 | 30 (31.3) | 30 (30.3) | 0.021 | 0.886 | 28 (28.6) | 32 (33.0) | 0.447 | 0.504 | 28 (28.0) | 32 (33.7) | 0.739 | 0.390 |
| Male | 135 | 66 (68.8) | 69 (69.7) | 70 (71.4) | 65 (67.0) | 72 (72.0) | 63 (66.3) | ||||||
| Age, years | |||||||||||||
| <65 | 120 | 60 (62.5) | 60 (60.6) | 0.074 | 0.786 | 66 (67.3) | 54 (55.7) | 2.808 | 0.094 | 59 (59.0) | 61 (64.2) | 0.559 | 0.455 |
| ≥65 | 75 | 36 (37.5) | 39 (39.4) | 32 (32.7) | 43 (44.3) | 41 (41.0) | 34 (35.8) | ||||||
| BMI, kg/m2 | |||||||||||||
| <18.5 | 59 | 29 (30.2) | 30 (30.3) | <0.001 | 0.989 | 40 (40.8) | 19 (19.6) | 10.411 | 0.001 | 33 (33.0) | 26 (27.4) | 0.732 | 0.392 |
| ≥18.5 | 136 | 67 (69.8) | 69 (69.7) | 58 (59.2) | 78 (80.4) | 67 (67.0) | 69 (72.6) | ||||||
| Drinking history | |||||||||||||
| No | 159 | 77 (80.2) | 82 (82.8) | 0.222 | 0.637 | 79 (80.6) | 80 (82.5) | 0.112 | 0.728 | 83 (83.0) | 76 (80.0) | 0.291 | 0.589 |
| Yes | 36 | 19 (19.8) | 17 (17.2) | 19 (19.4) | 17 (17.5) | 17 (17.0) | 19 (20.0) | ||||||
| Smoking history | |||||||||||||
| No | 126 | 63 (65.6) | 63 (63.6) | 0.084 | 0.772 | 63 (64.3) | 63 (64.9) | 0.009 | 0.923 | 65 (65.0) | 61 (64.2) | 0.013 | 0.908 |
| Yes | 69 | 33 (34.4) | 36 (36.4) | 35 (35.7) | 34 (35.1) | 35 (35.00) | 34 (35.8) | ||||||
| Liver metastasis | |||||||||||||
| No | 112 | 52 (54.2) | 60 (60.6) | 0.827 | 0.363 | 51 (52.0) | 61 (62.9) | 2.346 | 0.126 | 58 (58.0) | 54 (56.8) | 0.027 | 0.870 |
| Yes | 83 | 44 (45.8) | 39 (39.4) | 47 (48.0) | 36 (37.1) | 42 (42.0) | 41 (43.2) | ||||||
| Peritoneal metastasis | |||||||||||||
| No | 152 | 72 (75.0) | 80 (80.8) | 0.957 | 0.328 | 73 (74.5) | 79 (81.4) | 1.371 | 0.242 | 77 (77.0) | 75 (78.9) | 0.107 | 0.743 |
| Yes | 43 | 24 (25.0) | 19 (19.2) | 25 (25.5) | 18 (18.6) | 23 (23.0) | 20 (21.1) | ||||||
| PD-L1 expression, CPS | |||||||||||||
| <5 | 105 | 54 (56.3) | 51 (51.5) | 0.440 | 0.507 | 62 (63.3) | 43 (44.3) | 7.033 | 0.008 | 60 (60.0) | 45 (47.4) | 3.128 | 0.077 |
| ≥5 | 90 | 42 (43.8) | 48 (48.5) | 36 (36.7) | 54 (55.7) | 40 (40.0) | 50 (52.6) | ||||||
| MMR status | |||||||||||||
| pMMR | 178 | 88 (91.7) | 90 (90.9) | 0.035 | 0.851 | 92 (93.9) | 86 (88.7) | 1.668 | 0.197 | 91 (91.0) | 87 (91.6) | 0.021 | 0.886 |
| dMMR | 17 | 8 (8.3) | 9 (9.1) | 6 (6.1) | 11 (11.3) | 9 (9.0) | 8 (8.4) | ||||||
| Treatment line | |||||||||||||
| First line | 130 | 67 (69.8) | 63 (63.6) | 0.831 | 0.362 | 73 (74.5) | 57 (58.8) | 5.426 | 0.020 | 67 (67.0) | 63 (66.3) | 0.010 | 0.919 |
| Second line and beyond | 65 | 29 (30.2) | 36 (36.4) | 25 (25.5) | 40 (41.2) | 33 (33.0) | 32 (33.7) | ||||||
| CEA, µg/l | |||||||||||||
| <3 | 83 | 34 (35.4) | 49 (49.5) | 3.951 | 0.047 | 35 (35.7) | 48 (49.5) | 3.781 | 0.052 | 38 (38.0) | 45 (47.4) | 1.749 | 0.186 |
| ≥3 | 112 | 62 (64.6) | 50 (50.5) | 63 (64.3) | 49 (50.5) | 62 (62.0) | 50 (52.6) | ||||||
| CA-199, U/ml | |||||||||||||
| <37 | 121 | 53 (55.2) | 68 (68.7) | 3.760 | 0.052 | 61 (62.2) | 60 (61.9) | 0.003 | 0.955 | 62 (62.0) | 59 (62.1) | <0.001 | 0.988 |
| ≥37 | 74 | 43 (44.8) | 31 (31.3) | 37 (37.8) | 37 (38.1) | 38 (38.0) | 36 (37.9) | ||||||
| AFP, µg/l | |||||||||||||
| <15 | 168 | 78 (81.2) | 90 (90.9) | 3.812 | 0.051 | 77 (78.6) | 91 (93.8) | 9.495 | 0.002 | 85 (85.0) | 83 (87.4) | 0.229 | 0.632 |
| ≥15 | 27 | 18 (18.8) | 9 (9.1) | 21 (21.4) | 6 (6.2) | 15 (15.0) | 12 (12.6) | ||||||
PNI, ALI and AGR count data are presented as n (%). PNI, prognostic nutritional index; ALI, advanced lung cancer inflammation index; AGR, albumin-globulin ratio; BMI, body mass index; PD-L1, programmed cell death ligand-1; CPS, combined positive score; MMR, mismatch repair; dMMR, MMR deficient; pMMR, MMR proficient; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen19-9; AFP, α-fetoprotein.